La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Australian Clinical Labs Croissance future
Future contrôle des critères 4/6
Australian Clinical Labs is forecast to grow earnings and revenue by 21% and 4.6% per annum respectively. EPS is expected to grow by 20.8% per annum. Return on equity is forecast to be 21.6% in 3 years.
Informations clés
21.0%
Taux de croissance des bénéfices
20.8%
Taux de croissance du BPA
Healthcare croissance des bénéfices | 17.0% |
Taux de croissance des recettes | 4.6% |
Rendement futur des capitaux propres | 21.6% |
Couverture par les analystes | Good |
Dernière mise à jour | 06 Aug 2024 |
Mises à jour récentes de la croissance future
Recent updates
We Think Australian Clinical Labs (ASX:ACL) Is Taking Some Risk With Its Debt
Jun 20Are Investors Undervaluing Australian Clinical Labs Limited (ASX:ACL) By 46%?
Feb 21Is It Time To Consider Buying Australian Clinical Labs Limited (ASX:ACL)?
Dec 08Here's Why We Think Australian Clinical Labs (ASX:ACL) Might Deserve Your Attention Today
Aug 14Australian Clinical Labs Limited (ASX:ACL) Just Reported Half-Year Earnings: Have Analysts Changed Their Mind On The Stock?
Feb 25New Forecasts: Here's What Analysts Think The Future Holds For Australian Clinical Labs Limited (ASX:ACL)
Dec 22The Market Lifts Australian Clinical Labs Limited (ASX:ACL) Shares 31% But It Can Do More
Dec 21The Strong Earnings Posted By Australian Clinical Labs (ASX:ACL) Are A Good Indication Of The Strength Of The Business
Sep 01Prévisions de croissance des bénéfices et des revenus
Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
---|---|---|---|---|---|
6/30/2027 | 794 | 49 | 50 | 61 | 2 |
6/30/2026 | 749 | 44 | 76 | 174 | 8 |
6/30/2025 | 713 | 38 | 71 | 166 | 9 |
6/30/2024 | 685 | 28 | 60 | 151 | 9 |
12/31/2023 | 674 | 15 | 147 | 154 | N/A |
9/30/2023 | 686 | 26 | 142 | 149 | N/A |
6/30/2023 | 697 | 36 | 137 | 144 | N/A |
3/31/2023 | 757 | 55 | 143 | 154 | N/A |
12/31/2022 | 818 | 73 | 148 | 165 | N/A |
9/30/2022 | 907 | 126 | 206 | 225 | N/A |
6/30/2022 | 996 | 178 | 263 | 284 | N/A |
3/31/2022 | 931 | 156 | 238 | 256 | N/A |
12/31/2021 | 867 | 134 | 214 | 228 | N/A |
9/30/2021 | 757 | 97 | 179 | 191 | N/A |
6/30/2021 | 647 | 60 | 144 | 154 | N/A |
3/31/2021 | 598 | 79 | N/A | N/A | N/A |
12/31/2020 | 549 | 98 | N/A | N/A | N/A |
9/30/2020 | 520 | 70 | N/A | N/A | N/A |
6/30/2020 | 491 | 41 | 92 | 102 | N/A |
6/30/2019 | 448 | -11 | -13 | 1 | N/A |
6/30/2018 | 379 | -9 | -4 | 5 | N/A |
6/30/2017 | 340 | -24 | N/A | 5 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: ACL's forecast earnings growth (21% per year) is above the savings rate (2.4%).
Bénéfices vs marché: ACL's earnings (21% per year) are forecast to grow faster than the Australian market (13.1% per year).
Croissance élevée des bénéfices: ACL's earnings are expected to grow significantly over the next 3 years.
Chiffre d'affaires vs marché: ACL's revenue (4.6% per year) is forecast to grow slower than the Australian market (5.4% per year).
Croissance élevée des revenus: ACL's revenue (4.6% per year) is forecast to grow slower than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: ACL's Return on Equity is forecast to be high in 3 years time (21.6%)